Guidelines for radioiodine therapy of differentiated thyroid cancer

M Luster, SE Clarke, M Dietlein, M Lassmann… - European journal of …, 2008 - Springer
Introduction The purpose of the present guidelines on the radioiodine therapy (RAIT) of
differentiated thyroid cancer (DTC) formulated by the European Association of Nuclear …

Complications of radioactive iodine treatment of thyroid carcinoma

SL Lee - Journal of the National Comprehensive Cancer …, 2010 - jnccn.org
Radioactive iodine (RAI) in the form of 131 I has been used to treat thyroid cancer since
1946. RAI is used after thyroidectomy to ablate the residual normal thyroid remnant, as …

Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma

D Van Nostrand, F Atkins, F Yeganeh, E Acio… - Thyroid, 2002 - liebertpub.com
In the absence of definitive studies relating radioiodine dose to outcomes, selection of a
dose of radioiodine to treat metastatic thyroid carcinoma is problematic, and several …

[HTML][HTML] Radiolabeled cetuximab conjugates for EGFR targeted cancer diagnostics and therapy

W Sihver, J Pietzsch, M Krause, M Baumann… - Pharmaceuticals, 2014 - mdpi.com
The epidermal growth factor receptor (EGFR) has evolved over years into a main molecular
target for the treatment of different cancer entities. In this regard, the anti-EGFR antibody …

Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy

H Li, KW Peng, SJ Russell - Human gene therapy, 2012 - liebertpub.com
Oncolytic measles virus (MV) encoding the human thyroidal sodium iodide symporter (MV-
NIS) has proved to be safe after intraperitoneal or intravenous administration in patients with …

Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I

JC Sisson, BL Shulkin, S Lawson - Journal of Nuclear Medicine, 2003 - Soc Nuclear Med
There is no consensus on the amount of 131I for treatment of patients with well-differentiated
thyroid carcinoma; usual amounts vary widely. Body retention of 131I has been shown to be …

Uncommon causes of thyrotoxicosis

ES Mittra, RD Niederkohr, C Rodriguez… - Journal of Nuclear …, 2008 - Soc Nuclear Med
Apart from the common causes of thyrotoxicosis, such as Graves' disease and functioning
nodular goiters, there are more than 20 less common causes of elevated free thyroid …

Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid …

D Van Nostrand, F Atkins, S Moreau, M Aiken… - Thyroid, 2009 - liebertpub.com
Background: Dosimetry has been used to help identify when empiric dosages of 131-I
treatment for suspected metastatic well-differentiated thyroid carcinoma (WDTC) may be …

[HTML][HTML] An Artificial Intelligence System for Optimizing Radioactive Iodine Therapy Dosimetry

MF Georgiou, JA Nielsen, R Chiriboga… - Journal of clinical …, 2023 - mdpi.com
Thyroid cancer, specifically differentiated thyroid carcinoma (DTC), is one of the most
prevalent endocrine malignancies worldwide. Radioactive iodine therapy (RAIT) using I-131 …

Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole‐body …

M Salvatori, G Perotti, V Rufini… - Clinical …, 2004 - Wiley Online Library
Summary objective To evaluate the risk of performing inappropriate 131I ablative therapies
for thyroid carcinoma in patients lacking thyroid remnants or metastases, using a strategy of …